Tiberal (Ro 7-0207-Roche) in the Treatment of Intestinal Amoebiasis - Part II
Abstract
Twenty-four intestinal amoebiasis patients have been treated with a new amoebicid tiberal (Roche) or metronidazole as a control in a dosage of 15- 30 mg/kg body weight per day for 5 consecutive days. The results show that both drugs achieve a 100% cure rate. No side effects or signs of drug toxicity as evaluated from the results of the safety tests were observed. No signs of clinical or parasitological relapses were seen (after discharge. In comparison with the previous trial with a lower dosage (7~ - 15 mg.) and longer course (7 days) the results were even better, e.g. clinical improvement and parasitological disappearance were achieved in a shorter time.
References
2. PUDJIADI, S.H. and HARMANSES, S. : Survey on treatment of vitamin A deficiency in children. Paediatr. Indones. 5 : 612 (1965).
3. PUDJIADI, S.H.; SRI MULJANI DARMAWAN and MUSLICHAN, S. : lntestopan in the treatment of intestinal amoebiasis. Paediatr. Indones. 9 : 137 (1969).
4. PUD)IADI, S.H.; SUNOTO; SUHARJONO and NARTONO KADRI : A new oral amoebicid (Ro 7-0207) in the treatment of intestinal amoebiasis. Asian J. Med. 8 : 528 (1972).
5. ROCHE FAR EAST Ltd. HONGKONG: Data sheet on amoebicid (Ro 7-0207).
6. SHAH, J.R.; MEHTA, R.H.; PATEL, K.H. and PHUTANE, P.N. : Studies on amoebiasis. Indian. J. med. Sci. 14 : 98 (1960).
7. SRI ROCHANI SUDJARWO; HARDJATNO, H. and SUHARJONO: Clinical trial of oral dehydroemetine in the treatment of intestinal amoebiasis in children. Paediatr. Indones. 11 : 196 (1971).
Copyright (c) 2019 Sunoto Sunoto, S. H. Pudjiadi, Suharjono Suharjono, Z. Sulaiman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Published 2019-09-18